1
|
The Role of Systems Biology in Deciphering Asthma Heterogeneity. LIFE (BASEL, SWITZERLAND) 2022; 12:life12101562. [PMID: 36294997 PMCID: PMC9605413 DOI: 10.3390/life12101562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 09/28/2022] [Accepted: 10/04/2022] [Indexed: 11/17/2022]
Abstract
Asthma is one of the most common and lifelong and chronic inflammatory diseases characterized by inflammation, bronchial hyperresponsiveness, and airway obstruction episodes. It is a heterogeneous disease of varying and overlapping phenotypes with many confounding factors playing a role in disease susceptibility and management. Such multifactorial disorders will benefit from using systems biology as a strategy to elucidate molecular insights from complex, quantitative, massive clinical, and biological data that will help to understand the underlying disease mechanism, early detection, and treatment planning. Systems biology is an approach that uses the comprehensive understanding of living systems through bioinformatics, mathematical, and computational techniques to model diverse high-throughput molecular, cellular, and the physiologic profiling of healthy and diseased populations to define biological processes. The use of systems biology has helped understand and enrich our knowledge of asthma heterogeneity and molecular basis; however, such methods have their limitations. The translational benefits of these studies are few, and it is recommended to reanalyze the different studies and omics in conjugation with one another which may help understand the reasons for this variation and help overcome the limitations of understanding the heterogeneity in asthma pathology. In this review, we aim to show the different factors that play a role in asthma heterogeneity and how systems biology may aid in understanding and deciphering the molecular basis of asthma.
Collapse
|
2
|
Lad A, Breidenbach JD, Su RC, Murray J, Kuang R, Mascarenhas A, Najjar J, Patel S, Hegde P, Youssef M, Breuler J, Kleinhenz AL, Ault AP, Westrick JA, Modyanov NN, Kennedy DJ, Haller ST. As We Drink and Breathe: Adverse Health Effects of Microcystins and Other Harmful Algal Bloom Toxins in the Liver, Gut, Lungs and Beyond. Life (Basel) 2022; 12:life12030418. [PMID: 35330169 PMCID: PMC8950847 DOI: 10.3390/life12030418] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Revised: 03/03/2022] [Accepted: 03/08/2022] [Indexed: 12/19/2022] Open
Abstract
Freshwater harmful algal blooms (HABs) are increasing in number and severity worldwide. These HABs are chiefly composed of one or more species of cyanobacteria, also known as blue-green algae, such as Microcystis and Anabaena. Numerous HAB cyanobacterial species produce toxins (e.g., microcystin and anatoxin—collectively referred to as HAB toxins) that disrupt ecosystems, impact water and air quality, and deter recreation because they are harmful to both human and animal health. Exposure to these toxins can occur through ingestion, inhalation, or skin contact. Acute health effects of HAB toxins have been well documented and include symptoms such as nausea, vomiting, abdominal pain and diarrhea, headache, fever, and skin rashes. While these adverse effects typically increase with amount, duration, and frequency of exposure, susceptibility to HAB toxins may also be increased by the presence of comorbidities. The emerging science on potential long-term or chronic effects of HAB toxins with a particular emphasis on microcystins, especially in vulnerable populations such as those with pre-existing liver or gastrointestinal disease, is summarized herein. This review suggests additional research is needed to define at-risk populations who may be helped by preventative measures. Furthermore, studies are required to develop a mechanistic understanding of chronic, low-dose exposure to HAB toxins so that appropriate preventative, diagnostic, and therapeutic strategies can be created in a targeted fashion.
Collapse
Affiliation(s)
- Apurva Lad
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Joshua D. Breidenbach
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Robin C. Su
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Jordan Murray
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Rebecca Kuang
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Alison Mascarenhas
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - John Najjar
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Shivani Patel
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Prajwal Hegde
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Mirella Youssef
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Jason Breuler
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Andrew L. Kleinhenz
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - Andrew P. Ault
- Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA;
| | - Judy A. Westrick
- Lumigen Instrumentation Center, Department of Chemistry, Wayne State University, Detroit, MI 48202, USA;
| | - Nikolai N. Modyanov
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
| | - David J. Kennedy
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
- Correspondence: (D.J.K.); (S.T.H.); Tel.: +1-419-383-6822 (D.J.K.); +1-419-383-6859 (S.T.H.)
| | - Steven T. Haller
- College of Medicine and Life Science, University of Toledo, Toledo, OH 43614, USA; (A.L.); (J.D.B.); (R.C.S.); (J.M.); (R.K.); (A.M.); (J.N.); (S.P.); (P.H.); (M.Y.); (J.B.); (A.L.K.); (N.N.M.)
- Correspondence: (D.J.K.); (S.T.H.); Tel.: +1-419-383-6822 (D.J.K.); +1-419-383-6859 (S.T.H.)
| |
Collapse
|
3
|
Almansoori A, Bhamidimarri PM, Bendardaf R, Hamoudi R. In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma. Int J Gen Med 2022; 15:3097-3120. [PMID: 35330879 PMCID: PMC8939872 DOI: 10.2147/ijgm.s345336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Accepted: 02/25/2022] [Indexed: 11/23/2022] Open
Abstract
Background Purpose Methods Results Conclusion
Collapse
Affiliation(s)
- Asma Almansoori
- Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- Correspondence: Asma Almansoori; Rifat Hamoudi, Email ;
| | | | - Riyad Bendardaf
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
- Department of Oncology, University Hospital Sharjah, Sharjah, United Arab Emirates
| | - Rifat Hamoudi
- Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
- Division of Surgery and Interventional Science, University College London, London, UK
| |
Collapse
|